AI Generated Image
AstraZeneca details failed ATTR-CM study, affecting other biotechs
STAT • • business
Key Points:
- AstraZeneca announced the unexpected failure of a Phase 3 clinical trial for its experimental heart disease drug targeting ATTR-CM, as the drug showed no additional benefits for patients already on stabilizer medications.
- The trial's results were significantly impacted because most participants were already taking stabilizers, leading to no observed improvement with the addition of AstraZeneca’s silencer drug.
- This outcome affects not only AstraZeneca and its partner Ionis Pharmaceuticals but also other companies in the ATTR-CM market, such as Alnylam Pharmaceuticals and BridgeBio, which produce silencers and stabilizers respectively.
- Analysts suggest the trial reinforces the potential superiority of oral stabilizer drugs over injectable silencers for treating ATTR-CM, influencing future treatment approaches and market dynamics.
